Recombinant Human CDK1/CyclinA2 (N-GST tag)
Catalog No : IGX-RP761
366.40€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | Recombinant Human CDK1/CyclinA2 (N-GST tag) | ||
|---|---|---|---|
| Catalog No | IGX-RP761 | ||
| Supplier’s Catalog No | IGX-RP761 | ||
| Supplier | ImuGeX | ||
| Source antigen | Insect cells | ||
| Reactivity | Human | ||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | 59 | ||
| Storage | -70°C | ||
|---|---|---|---|
| Other names | CDK1: CDC2 CDC28A; MGC111195; DKFZp686L20222 CyclinA2: CCN1; CCNA | ||
| Grade | Highly Purified | ||
| Purity | 70% - 90% | ||
| Form | 50mM Tris-HCl, pH 7.5, 150mM NaCl, 0.25mM DTT, 0.1mM EGTA, 0.1mM EDTA, 0.1mM PMSF, 25% glycerol. | ||
| Reactivity life | 6 months | ||
| Note | For reserch purpose only | ||
| Purity | 70% - 90% | ||
| Description | CDK1 or Cell Division Control protein 1 is essential for the completion of START, the controlling event in the cell cycle that is required to initiate mitosis. CDK1 is a catalytic subunit of a protein kinase complex, called the M-Phase Promoting Factor that induces entry into mitosis and is universal among eukaryotes . Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis. Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer has also been demonstrated . | ||
Product Details
© 2020 Imugex All Rights Reserved